▶ 調査レポート

血漿プロテアーゼC1阻害剤治療の世界市場2020年:企業別、地域別、種類・用途別

• 英文タイトル:Global Plasma Protease C1-inhibitor Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。血漿プロテアーゼC1阻害剤治療の世界市場2020年:企業別、地域別、種類・用途別 / Global Plasma Protease C1-inhibitor Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / D0GIR-02286資料のイメージです。• レポートコード:D0GIR-02286
• 出版社/出版日:GlobalInfoResearch / 2020年9月23日
• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール
• 産業分類:医療、製薬、バイオ
• 販売価格(消費税別)
  Single User¥382,800 (USD3,480)▷ お問い合わせ
  Multi User¥574,200 (USD5,220)▷ お問い合わせ
  Corporate User¥765,600 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、血漿プロテアーゼC1阻害剤治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。血漿プロテアーゼC1阻害剤治療の種類別市場規模(C1阻害剤、カリクレイン阻害剤(カルビトール))、用途別市場規模(病院薬局、独立薬局、アウトレット)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Takeda、Pharming Group N.V.、CSL Limited、Sanquin
・地域別グローバル市場分析 2015年-2020年
・血漿プロテアーゼC1阻害剤治療の北米市場(アメリカ、カナダ、メキシコ)
・血漿プロテアーゼC1阻害剤治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・血漿プロテアーゼC1阻害剤治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・血漿プロテアーゼC1阻害剤治療の南米市場(ブラジル、アルゼンチン)
・血漿プロテアーゼC1阻害剤治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:C1阻害剤、カリクレイン阻害剤(カルビトール)
・用途別分析:病院薬局、独立薬局、アウトレット
・地域別市場規模予測 2021年-2025年
・調査の結果・結論

Market Overview
The global Plasma Protease C1-inhibitor Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Plasma Protease C1-inhibitor Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Plasma Protease C1-inhibitor Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Plasma Protease C1-inhibitor Treatment market has been segmented into:
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)

By Application, Plasma Protease C1-inhibitor Treatment has been segmented into:
Hospital Pharmacies
Independent Pharmacies and Outlets

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Plasma Protease C1-inhibitor Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Plasma Protease C1-inhibitor Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Plasma Protease C1-inhibitor Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Plasma Protease C1-inhibitor Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Plasma Protease C1-inhibitor Treatment Market Share Analysis
Plasma Protease C1-inhibitor Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Plasma Protease C1-inhibitor Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Plasma Protease C1-inhibitor Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Plasma Protease C1-inhibitor Treatment are:
Takeda
Pharming Group N.V.
CSL Limited
Sanquin

レポート目次

Table of Contents

1 Plasma Protease C1-inhibitor Treatment Market Overview
1.1 Product Overview and Scope of Plasma Protease C1-inhibitor Treatment
1.2 Classification of Plasma Protease C1-inhibitor Treatment by Type
1.2.1 Global Plasma Protease C1-inhibitor Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Type in 2019
1.2.3 C1-inhibitors
1.2.4 Kallikrein Inhibitor (Kalbitor)
1.3 Global Plasma Protease C1-inhibitor Treatment Market by Application
1.3.1 Overview: Global Plasma Protease C1-inhibitor Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Independent Pharmacies and Outlets
1.4 Global Plasma Protease C1-inhibitor Treatment Market by Regions
1.4.1 Global Plasma Protease C1-inhibitor Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Plasma Protease C1-inhibitor Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Plasma Protease C1-inhibitor Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Plasma Protease C1-inhibitor Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Plasma Protease C1-inhibitor Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Plasma Protease C1-inhibitor Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Plasma Protease C1-inhibitor Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Takeda SWOT Analysis
2.1.4 Takeda Product and Services
2.1.5 Takeda Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pharming Group N.V.
2.2.1 Pharming Group N.V. Details
2.2.2 Pharming Group N.V. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pharming Group N.V. SWOT Analysis
2.2.4 Pharming Group N.V. Product and Services
2.2.5 Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 CSL Limited
2.3.1 CSL Limited Details
2.3.2 CSL Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 CSL Limited SWOT Analysis
2.3.4 CSL Limited Product and Services
2.3.5 CSL Limited Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sanquin
2.4.1 Sanquin Details
2.4.2 Sanquin Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sanquin SWOT Analysis
2.4.4 Sanquin Product and Services
2.4.5 Sanquin Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Plasma Protease C1-inhibitor Treatment Players Market Share
3.2.2 Top 10 Plasma Protease C1-inhibitor Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Regions
4.2 North America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
5 North America Plasma Protease C1-inhibitor Treatment Revenue by Countries
5.1 North America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
5.2 USA Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
6 Europe Plasma Protease C1-inhibitor Treatment Revenue by Countries
6.1 Europe Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
6.2 Germany Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
6.4 France Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue by Countries
7.1 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
7.2 China Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
7.5 India Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
8 South America Plasma Protease C1-inhibitor Treatment Revenue by Countries
8.1 South America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
8.2 Brazil Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Plasma Protease C1-inhibitor Treatment by Countries
9.1 Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Plasma Protease C1-inhibitor Treatment Market Forecast by Type (2019-2024)
10.3 C1-inhibitors Revenue Growth Rate (2015-2025)
10.4 Kallikrein Inhibitor (Kalbitor) Revenue Growth Rate (2015-2025)
11 Global Plasma Protease C1-inhibitor Treatment Market Segment by Application
11.1 Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Application (2015-2020)
11.2 Plasma Protease C1-inhibitor Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Independent Pharmacies and Outlets Revenue Growth (2015-2020)
12 Global Plasma Protease C1-inhibitor Treatment Market Size Forecast (2021-2025)
12.1 Global Plasma Protease C1-inhibitor Treatment Market Size Forecast (2021-2025)
12.2 Global Plasma Protease C1-inhibitor Treatment Market Forecast by Regions (2021-2025)
12.3 North America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
12.6 South America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Plasma Protease C1-inhibitor Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Plasma Protease C1-inhibitor Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Plasma Protease C1-inhibitor Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Plasma Protease C1-inhibitor Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Takeda Corporate Information, Location and Competitors
Table 6. Takeda Plasma Protease C1-inhibitor Treatment Major Business
Table 7. Takeda Plasma Protease C1-inhibitor Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Takeda SWOT Analysis
Table 9. Takeda Plasma Protease C1-inhibitor Treatment Product and Solutions
Table 10. Takeda Plasma Protease C1-inhibitor Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Pharming Group N.V. Corporate Information, Location and Competitors
Table 12. Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Major Business
Table 13. Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Pharming Group N.V. SWOT Analysis
Table 15. Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Product and Solutions
Table 16. Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. CSL Limited Corporate Information, Location and Competitors
Table 18. CSL Limited Plasma Protease C1-inhibitor Treatment Major Business
Table 19. CSL Limited Plasma Protease C1-inhibitor Treatment Total Revenue (USD Million) (2017-2018)
Table 20. CSL Limited SWOT Analysis
Table 21. CSL Limited Plasma Protease C1-inhibitor Treatment Product and Solutions
Table 22. CSL Limited Plasma Protease C1-inhibitor Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Sanquin Corporate Information, Location and Competitors
Table 24. Sanquin Plasma Protease C1-inhibitor Treatment Major Business
Table 25. Sanquin Plasma Protease C1-inhibitor Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Sanquin SWOT Analysis
Table 27. Sanquin Plasma Protease C1-inhibitor Treatment Product and Solutions
Table 28. Sanquin Plasma Protease C1-inhibitor Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Players (2015-2020)
Table 30. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Players (2015-2020)
Table 31. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Regions (2015-2020)
Table 32. Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Regions (2015-2020)
Table 33. North America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
Table 34. North America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Table 35. Europe Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Countries (2015-2020)
Table 36. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Countries (2015-2020)
Table 37. South America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2015-2020)
Table 38. South America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Table 39. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Countries (2015-2020)
Table 40. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Table 41. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Type (2015-2020)
Table 42. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Type (2015-2020)
Table 43. Global Plasma Protease C1-inhibitor Treatment Revenue Forecast by Type (2021-2025)
Table 44. Global Plasma Protease C1-inhibitor Treatment Revenue by Application (2015-2020)
Table 45. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Application (2015-2020)
Table 46. Global Plasma Protease C1-inhibitor Treatment Revenue Forecast by Application (2021-2025)
Table 47. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Plasma Protease C1-inhibitor Treatment Picture
Figure 2. Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Type in 2019
Figure 3. C1-inhibitors Picture
Figure 4. Kallikrein Inhibitor (Kalbitor) Picture
Figure 5. Plasma Protease C1-inhibitor Treatment Revenue Market Share by Application in 2019
Figure 6. Hospital Pharmacies Picture
Figure 7. Independent Pharmacies and Outlets Picture
Figure 8. Global Plasma Protease C1-inhibitor Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Plasma Protease C1-inhibitor Treatment Revenue Market Share in 2019
Figure 17. Global Top 10 Players Plasma Protease C1-inhibitor Treatment Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Regions (2015-2020)
Figure 21. Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Regions in 2018
Figure 22. North America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 23. Europe Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 25. South America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 27. North America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Figure 28. North America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries in 2019
Figure 29. USA Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Canada Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 32. Europe Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries in 2019
Figure 34. Germany Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 35. UK Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 36. France Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 37. Russia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 38. Italy Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries in 2019
Figure 41. China Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Japan Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Korea Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 44. India Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 46. South America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Figure 47. South America Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries in 2019
Figure 48. Brazil Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 53. UAE Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Type (2015-2020)
Figure 57. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Type in 2019
Figure 58. Global Plasma Protease C1-inhibitor Treatment Market Share Forecast by Type (2021-2025)
Figure 59. Global C1-inhibitors Revenue Growth Rate (2015-2020)
Figure 60. Global Kallikrein Inhibitor (Kalbitor) Revenue Growth Rate (2015-2020)
Figure 61. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Application (2015-2020)
Figure 62. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Application in 2019
Figure 63. Global Plasma Protease C1-inhibitor Treatment Market Share Forecast by Application (2021-2025)
Figure 64. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 65. Global Independent Pharmacies and Outlets Revenue Growth Rate (2015-2020)
Figure 66. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Plasma Protease C1-inhibitor Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Plasma Protease C1-inhibitor Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
Figure 70. Europe Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
Figure 72. South America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel